Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population

NCT03593655 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

247

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DEVICE: Dapivirine vaginal ring
DRUG: FTC/TDF

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)